Pharmaceutical

STAT+: Dana-Farber cancer researchers moving to retract...

“The frequency of these allegations has gone into some sort of hyper-exponential...

STAT+: FDA scolds Novartis over a misleading TV ad for ...

The FDA has scolded Novartis for making false and misleading statements about a ...

Feds bar Theranos founder Elizabeth Holmes from governm...

Theranos founder and ex-CEO Elizabeth Holmes is banned from federal health progr...

STAT+: Pharmalittle: We’re reading about Sanders target...

U.S. Sen. Bernie Sanders has taken a step toward subpoenaing the CEOs of Johnson...

The Senate health committee looks into its first subpoe...

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Hospitals offer their custom-built tech for sale...

Large health systems like Mayo Clinic and Mass General Brigham are looking for n...

Opinion: Clogged arteries: the unseen cost of road-bloc...

If protesters were aware of the extent to which those with life-threatening medi...

Opinion: STAT+: The necessary roughness of 2023 has set...

The necessary roughness of 2023 has set up a very promising 2024 for the biotech...

Synendos set to study endocannabinoid inhibitor for neu...

The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients t...

Davos: AI Governance Alliance calls for stronger global...

The AI Governance Alliance has called for stronger collaboration to create a fra...

Biotech layoffs strike hard with PMV Pharma, Ikena, and...

The layoffs will free cash resources that will extend financial runways and focu...

NSCF embarks on fifth flight to investigate neurodegene...

Information gathered from the study will guide an upcoming two-week mission sche...

Call for earlier diagnosis to improve Gaucher disease o...

Delayed diagnoses in many Gaucher disease patients contribute to slower-than-opt...

Ikena fires 35% of staff to funnel funds into clinical ...

Ikena has also paused exploratory research and discovery in addition to workforc...

FDA declines to approve Satsuma’s migraine treatment ST...

The US FDA has declined to grant approval for Satsuma Pharmaceuticals’ STS101 fo...

FDA grants fast track designation for Verastem’s NSCLC ...

The US FDA has granted fast track designation for Verastem’s avutometinib for tr...